Rationale and design of the POLEM trial: avelumab plus fluoropyrimidine-based chemotherapy as adjuvant treatment for stage III mismatch repair deficient or POLE exonuclease domain... 由 Lau, D, Kalaitzaki, E, Church, DN, Pandha, H, Tomlinson, I, Annels, N, Gerlinger, M, Sclafani, F, Smith, G, Begum, R, Crux, R, Gillbanks, A, Wordsworth, S, Chau, I, Starling, N, Cunningham, D, Dhillon, T